Staphylococcus Lugdunensis Prosthetic Joint Infection

Study Overview
=================
Brief Summary
-----------------
Staphylococcus lugdunensis is a coagulase-negative staphylococcus belonging to the human commensal cutaneous flora, and has been little studied in the field of prosthetic joint infections. However, it shares many virulence traits with Staphylococcus aureus, including many adhesins and its ability to form biofilm, and the few series of cases reports a significant failure rate.

Official Title
-----------------
Staphylococcus Lugdunensis Prosthetic Joint Infection: a Retrospective Cohort Study

Conditions
-----------------
Staphylococcal Infections, Prosthetic Joint Infection

Intervention / Treatment
-----------------
* Other: Prothestic joint infection due to Staphylococcus lugdunensis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: infection of joint prosthesis (whatever its type) with Staphylococcus lugdunensis defined by the positivity of at least 2 gold-standard samples (joint puncture, intraoperative samples) with S. lugdunensis; OR a single positive gold-standard sample or positive blood cultures AND formal clinical, radiological, biological and / or pathological arguments in favor of an infection of joint prosthesis AND absence of other pathogenic agent Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Prothestic joint infection due to Staphylococcus lugdunensis<br>Patients having had a prosthetic joint infection with Staphylococcus lugdunensis | Other: Prothestic joint infection due to Staphylococcus lugdunensis<br>* description of prosthetic joint infection with Staphylococcus lugdunensis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of PJI infection with Staphylococcus lugdunensis | proportion of patients having PJI infection with Staphylococcus lugdunensis, alone or with other bacteria | between 2010 and 2020 | 
| Description of PJI infection with Staphylococcus lugdunensis : type | type of PJI : knee or hip prosthesis | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 
| Description of PJI infection with Staphylococcus lugdunensis : evolution | evolution of PJI :evolution between prosthesis placement and the onset of symptoms, gateway to infection | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 
| Description of patients with PJI infection due to Staphylococcus lugdunensis | type of patients: age, CMI | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 
| Description of patients with PJI infection due to Staphylococcus lugdunensis : follow up | duration of the follow up of patients | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 
| Description of patients with PJI infection due to Staphylococcus lugdunensis : medical treatment | description and duration of antibiotics | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 
| Description of patients with PJI infection due to Staphylococcus lugdunensis : surgical treatment | description of surgery performed : DAIR, one-step exchange, two-step exchange | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 
| rate of treatment failure | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biofilm, Staphylococcus lugdunensis, Prosthetic Joint Infection